PhotoCure ASA announces today that Metvix has been approved for Bowen's disease.
PhotoCure ASA announces today that Metvix has been approved for Bowen's disease. The new indication is approved in 22 EU/EEA countries through the European Mutual Recognition Procedure. As for other approved dermatological indications, Galderma will be responsible for the marketing and sales of Metvix in markets outside the Nordic region.
Bowen's disease is a non-melanoma skin cancer also known as squamous cell carcinoma (SCC) in situ. It usually appears as a slow-growing red and scaly patch, and is thought to develop partly as a result of long-term sun exposure. US studies indicate that the incidence of Bowen's disease in caucasians ranges from 15-140/100 000.
Kjetil Hestdal, President and CEO of PhotoCure, says: "The approval for Bowen's has been achieved thanks to a joint effort between PhotoCure and our partner Galderma. The Metvix treatment is effective and non-invasive, and will give this patient group a new, much-needed treatment option."